For citations:
Potapenko V.G., Baumert E.V., Bobrova A.A., Vashchenkov R.V., Dorofeeva N.V., Kaplanov K.D., Karyagina E.V., Levanov A.N., Luchinin A.S., Moiseev S.I., Novitskii A.V., Nizamutdinova A.S., Pirogova О.V., Povzun S.A., Platonov М.V., Porunova V.V., Ptashnikov D.А., Ryabchikova V.V., Simeniv S.Ya., Skorokhod I.А., Ukrainchenko Е.А., Chaginskaya D.А., Shelekhova T.V., Shirokova M.N., Shutylev A.A., Medvedeva N.V. Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study. Oncohematology. 2022;17(3):48-61. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-3-48-61
Email this article 